Minimally invasive lung volume reduction for localized emphysema
Official title: Efficacy and Safety of 0.5% w/v Nano- Silver Nitrate Versus Silver Nitrate Solution for Bronchoscopic Lung Volume Reduction in Management of Localized Emphysema: Prospective Interventional Randomized Controlled Clinical Trial
Run by Mansoura University Hospital · NCT06629558 · Data updated 2026-11-12
This study is testing a new way to treat localized emphysema in COPD patients by using a special technique to reduce lung size and improve breathing.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 75 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Mansoura University Hospital Academic / other |
| Locations | 1 site (Al Mansurah) |
| Status | Recruiting |
| Started | October 1, 2024 |
| Main results expected | December 1, 2025 |
| Study ends | March 1, 2026 |
| Registry record updated | May 29, 2025 |
| Trial ID | NCT06629558 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients under 75 years old with grade III or IV COPD and localized emphysema who are not suitable for surgical lung volume reduction.
✕Probably not a fit
Patients with significant co-morbidities, homogeneous emphysema, or those over 75 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of bronchoscopic lung volume reduction (BLVR) techniques to treat localized emphysema in patients with chronic obstructive pulmonary disease (COPD). The approach involves the endobronchial delivery of silver nitrate to occlude or ablate emphysematous lung tissue, aiming to reduce lung hyperinflation and improve lung function. Patients eligible for this intervention are those with significant respiratory symptoms despite optimal medical therapy and specific lung function criteria. The study will assess the effectiveness of this chemical agent in enhancing lung capacity and overall patient well-being.
Why it matters
Potential benefit: If successful, this treatment could significantly improve lung function and quality of life for patients suffering from localized emphysema.
How similar studies have gone: Previous studies using bronchoscopic lung volume reduction techniques have shown promising results, indicating a potential for success with this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * COPD of grade III and IV according to GOLD 2024 staging of COPD with localized (heterogeneous) emphysema as determined by high resolution computerized tomography (HRCT) of the chest with area of destruction \>-950 Hounsfield units (HU) and respiratory symptoms despite optimal medical therapy with the following criteria: Patient less than 75 years of age not candidate for or had refused lung volume reduction surgery but fit for fibro-optic bronchoscope (FOB). Lung volumes criteria: FEV1 less than 60% of predicted value, Residual volume (RV) more than 100% of predicted value, Total lung capacity (TLC) more than 100% of predicted value, 6 MWT of less than 450 meters. Exclusion Criteria: * Significant co-morbidities that limits exercise capacity or prognosis as cardiovascular diseases (heart failure, arrhythmia, ischemic heart disease) and lung cancer. * Patients unfit or refused FOB. * Homogenous emphysema. * More than 75 years of age. * Associated lung fibrosis. * FEV1 \> 60%. * Current smoker.
Where it's running
-
Mohamed AbdElmoniem
Al Mansurah, Egypt Recruiting
Study contacts
- Principal investigator: Mohamed AbdElmoniem — Mansoura University
- Study coordinator: Mohamed AbdElmoniem
- Email: dr.m1993@mans.edu.eg
- Phone: 01014008473
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Venous leakage ED: embolosclerotherapy vs deep dorsal vein revascularization
This trial tests whether embolizing the veins around the penis or reconstructing the deep dorsal vein helps men with erectile dysfunction caused by venous leaks.
-
MMR vaccine injections into lesions for stubborn ringworm of the body and groin (tinea corporis and cruris)
This pilot will test whether injecting the MMR vaccine into affected skin can help people ages 10–60 with tinea corporis or cruris that hasn't responded to standard antifungal treatments.
-
Oral roflumilast for people 12 and older with moderate-to-severe atopic dermatitis
This 12-week pilot will test whether taking oral roflumilast once daily helps people aged 12 and older with moderate-to-severe atopic dermatitis.
-
Oral roflumilast treatment for adults with moderate-to-severe plaque psoriasis
This 12-week pilot will try daily oral roflumilast to see if it safely reduces psoriasis symptoms in adults with moderate-to-severe plaque psoriasis.
-
Demographics of lung cancer in women at Mansoura University
This project looks at demographic, smoking and exposure information from women diagnosed with primary bronchogenic lung cancer at Mansoura University over the past 10 years to see which factors are linked to their disease.
-
Adding MRI diffusion and mammogram micro‑calcifications to the Kaiser Score for BI-RADS 4 breast lesions
This project will test whether adding MRI diffusion measurements and mammogram micro‑calcification findings to the Kaiser Score can better identify which BI‑RADS 4 breast lesions need a biopsy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.